TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways

Hormone therapy drugs, such as bicalutamide and enzalutamide, directed against prostate cancer focus on androgen receptor (AR) signaling and are initially effective, but the disease progresses to lethality as resistance to these drugs develops. A method to prolong the drug response time and improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chao, Wang, Shangqian, Qin, Chao, Bao, Meilin, Cheng, Gong, Liu, Bianjiang, Shao, Pengfei, Lv, Qiang, Song, Ninghong, Hua, Lixin, Gu, Min, Li, Jie, Wang, Zengjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833828/
https://www.ncbi.nlm.nih.gov/pubmed/29449534
http://dx.doi.org/10.1038/s41419-017-0197-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833828/
https://www.ncbi.nlm.nih.gov/pubmed/29449534
http://dx.doi.org/10.1038/s41419-017-0197-y

Ejemplares similares